Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Fifth Avenue WALTHAM MA 02451 |
Tel: | 1-617-5998178 |
Website: | https://apellis.com |
IR: | See website |
Key People | ||
Cedric Francois President, Chief Executive Officer, Co-Founder, Director | Mark Delong Chief Business and Strategy Officer | Pascal Deschatelets Co-Founder, Chief Scientific Officer |
Timothy Sullivan Chief Financial Officer, Treasurer | Nur Nicholson Chief Technical Operations Officer | Adam J. Townsend Chief Operating Officer |
Karen Lewis Chief People Officer | James G. Chopas Chief Accounting Officer, Vice President, Corporate Controller | David O. Watson General Counsel | Caroline Baumal Chief Medical Officer |
Business Overview |
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company's approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom. |
Financial Overview |
For the three months ended 31 March 2024, Apellis Pharmaceuticals Inc revenues increased from $44.8M to $172.3M. Net loss decreased 63% to $66.4M. Revenues reflect SYFOVRE segment increase from $18.4M to $137.5M, EMPAVELI segment increase of 25% to $25.6M. Lower net loss reflects Compensation and related personnel costs decrease of 35% to $32.5M (expense), Research and Development - Balancing val decrease of 13% to $52.2M (expense). |